Twitter LinkedIn YouTube Amazon Alexa iTune Podcast Google Podcasts Spotify

MedX Health Corp. TSXV: MDX

InvestorIntel Features on MedX Health Corp.

Market Drivers interviews MedX Health on technology that allows early detection of skin cancer

“MedX has put together a platform that allows us to do early detection of skin cancer…Everything has been completed in […]

Company Overview

TeamWebsite

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin cancer with its DermSecure™ telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA (US), ARTG and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

News Releases

View All News

Twitter LinkedIn YouTube Amazon Alexa iTune Podcast Google Podcasts Spotify